Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Unknown3

Clinical Trials (3)

Showing 3 of 3 trials
NCT03617432Phase 2UnknownPrimary

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

NCT03611231Phase 2UnknownPrimary

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

NCT03494634Phase 2UnknownPrimary

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Showing all 3 trials

Research Network

Activity Timeline